BacVax

BacVax is a pre-clinical stage biotechnology company dedicated to developing next-generation vaccines against complex bacterial pathogens. Leveraging technology licensed from Emory University, the company focuses on preventing infections caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, which are leading causes of pneumonia and otitis media. Their approach involves a proprietary platform that presents a broad array of surface antigens to elicit a comprehensive immune response, aiming to overcome the limitations of current conjugate vaccines. The company's lead programs are designed to provide universal protection across various serotypes, potentially reducing the need for frequent vaccine updates. BacVax is positioned to address significant unmet needs in both pediatric and adult respiratory health globally.